European journal of pharmacology
CRISPR/Cas9-based genome-wide screen reveals a synergistic effect of Irinotecan and USP1 inhibitor in colorectal cancer.
Lei Wang, Min Miao, Lijing Bao, Junfeng Chu, Juan Zhou, Wenbo Song, Peipei Cai, Chen Cheng, Hongye Xu, Tao Wang, Rongrong Zhao, Hang Wang, Feng Liu, Ming Xu, Guangyu Tian
Published: 202610.1016/j.ejphar.2026.178558
Abstract
Irinotecan resistance remains a significant challenge in metastatic colorectal cancer (mCRC) therapy. To address this, we identified USP1 as a synthetic lethal partner of Irinotecan through genome-wide CRISPR/Cas9 screening in HCT-116 cells. Combinin…
Preview only. Read the full abstract at the source